ArticleWorld journal of surgical oncology2026
The association of survival with adjuvant chemotherapy in patients with ypTNM stage I gastric cancer after neoadjuvant chemotherapy.
Article in World journal of surgical oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
backgroundNeoadjuvant chemotherapy (NAC) combined with gastrectomy has been a standard therapeutic strategy for resectable gastric cancer (GC). However, it remains unclear whether postoperative adjuvant chemotherapy (AC) brings better survival in ypTNM stage I GC patients.
methodsData on ypTNM stage I GC patients with or without AC following systemic NAC and radical gastrectomy were retrospectively retrieved from the Surveillance, Epidemiology, and End Results (SEER) database between 2010 and 2021. Inverse probability of treatment weighting (IPTW) was used to balance covariates. Overall survival (OS) and cancer-specific survival (CSS) were assessed through Kaplan-Meier and Cox proportional hazards models. Two nomograms were developed to predict OS and CSS of patients with ypTNM stage I GC who received AC.
results661 patients met the inclusion criteria, 230 received AC and 431 were AC nonuser. AC was significantly associated with improved OS (weighted HR = 0.63, 95% CI: 0.43-0.92) but not statistically significant for CSS (weighted HR = 0.73, 95% CI: 0.46-1.17) after IPTW adjustment. Age, tumor diameter, and primary site were also independent predictors of survival. Subgroup analysis revealed that patients with non-proximal GC benefitted more from AC. The survival prediction models demonstrated good calibration and discrimination, with the C-indexes for OS were 0.75 and 0.79 for CSS.
conclusionPatients with ypTNM stage I GC might benefit from postoperative AC compared with non-AC. Nomograms showed better predictive value for evaluating the prognosis of ypTNM stage I GC patients who received AC.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.